- Mueller N. Overview of the epidemiology of malignancy in immune de ciency. J Acquir Immune De? c Syndr 1999; 21 (Suppl 1): 5-10.
- Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunode? ciencies. J Pediatrics 1995; 126: 1-10.
- Beral V, Newton R. Overview of the epidemiology of im-munode ciency associated cancers. J Natl Cancer Inst Monographs 1998; 23: 1-5.
- Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunode ciency virus type 1. J Natl Cancer Inst 1994; 86: 1711-6.
- Jones Jl, Hanson DL, Dworkin MS, Ward JW, Jaffe HW and the Adult:Adolescent spectrum of HIV disease. Effect of antiretroviral therapy on recent trends in selected cancers among HIV‘infected persons. J Acquir Immune De c Syndr 1999; 21 (Suppl 1): S11-S7.
- Cote TR, Biggar RJ, Rosenberg PS, et al. Non‘Hodgkin‘s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS:Cancer Study Group. Int J Cancer 1997; 73: 645-50.
- Ratner L, Redden D, Hamzeh F, et al. Chemotherapy for HIV associated non-Hodgkin‘s lymphoma in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity. Third National AIDS Malignancy Conference, Bethesda, MD, 1999 (Abstract 92).
- Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunode ciency virus infection. N Engl J Med 1992; 326: 1037-42.
- Palella FJ, Delaney KM, Moornan AC, et al. Declining morbidity and mortality among patients with advanced human immunode? ciency virus infection. N Engl J Med 1998; 338:853-60.
- Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunode? ciency virus infection and CD4 counts of 2000 per cubic milimeter or less. N Engl J Med 1997;337:725-33.
- Centers for Disease Control and Prevention Update. Trends in AIDS incidence, deaths, and prevalence--United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46: 861-867.
- Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classi? cation of hematological malignancies. Report of the clinical advisory committee meeting, Airlie House, Virginia. Mod Pathol 1997; 13: 193-207.
- Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin‘s disease staging classi? cation. Cancer Res 1971; 31: 1860-1.
- Kimby E, Brandt L, Nygren P, Glimelius B. A systematic overviewofchemotherapyeffectsinaggressivenon-Hodgkin‘s lymphoma. Acta Oncol 2001; 40: 198-212.
- Hanna GJ, Hirsch MS., Antiretroviral therapy of human imunode? ciency virus infection. In: Mandell GL, Bennett JE Dolin R, eds. Priciples and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2000: 1479-99.
- Cheson BD, Horning SJ, Coif? er B, et al. Report of an international workshop to standardize response criteria for Non-Hodgkin‘s lymphomas. J Clin Oncol 1999; 17: 1244-53.
- Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census (letter). N Engl J Med 1997; 336: 1531-2.
- Centers for Disease Control and Prevention. Report of the NIH panel to de? ne principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 5: 1-82.
- Kaplan L. Therapeutic approaches to HIV-associated non-Hodgkin‘s lymphoma., The American Society of Hematology Education Program Book 1999; 522-528.
- Vaccher E, Tirelli U, Spina M, et al. Age and serum lactate dehydrogenase level are independent prognostic factors in humanimmunode? ciencyvirus-relatednon-Hodgkin‘s lymphoma: a single-institute study of 96 patients. J Clin Oncol 1996; 14: 2217-22.
- Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of HIV-associated non-Hodgkin‘s lymphoma. Analysis of AIDS Malignancy Clinical Group (ACTG) protocol 142: low-dose vs. standard-dose m-BACOD GM-CSF. J Clin Oncol 1998; 16: 3601-11.
- Tirelli U, Spina M, Gabarre J, et al. Treatment of HIV-related non-Hodgkin‘s lymphoma adapted to prognostic factors. Third National AIDS Malignacy Conference, Bethesda, MD, 1999 (Abstract 91).
- Bower M, Sten S, Fife K, Nelson M, Gazzard BG. Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma. Eur J Cancer 2000; 36: 363-7.
- Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. JAMA 1991; 266: 84-90.
- Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunode? ciency virus related lymphoma treated with intensive combination chemotherapy. Am J Med 1993; 95: 188 -96.
- Tirelli U, Errante D, Spina M, et al. Second-line chemotherapy inhumanimmunode? ciency virus-associated non-Hodgkin‘s lymphoma. Cancer 1996; 77: 2127-31.
- for the French Italian Cooperative Study Group, Tirelli U, Errante D, Oksenhendler E, et al. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor prognosis AIDS-related non-Hodgkin‘s lymphoma. Ann Oncol 1992; 3: 843-7.
- Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effectsofrecombinanthumangranulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunode? ciency virus-associated non-Hodgkin‘s lymphoma: results of a randomized trial. J Clin Oncol 1991; 9: 929 -40.
- Kaplan LD, Straus DJ, Testa MA, et al. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin‘s lymphoma associated with human immuno-def? ciency virus infection. N Engl J Med 1997; 336: 1642-8.
- Navarro JT, Ribera JM, Oriol A, et al. Effect of highly active antiretroviral therapy (HAART) on response to therapy and survivalinpatientswithAIDS-relatednon-Hodgkin‘s lymphoma treated with CHOP. Blood 1999; 94: 525a.
- Vaccher E, Spina M, Talamani R, et al., Concomitant CHOP chemotherapy and HAART in patients with HIV-related non-Hodgkin‘s lymphoma. Proc Am Soc Clin Oncol 1998; 17: 47a (Abstract 184).
- Bower M, Matthews G, Powles T, Mandalia S, Nelson M, Gazzard BL. Changes in AIDS-related lymphoma (ARL) in the era of highly active antiretroviral therapy (HAART). J Clin Oncol 2000; 19: 17a.
Free access
Impact of Highly Active Antiretroviral Therapy in the Treatment of HIV–Infected Patients with Systemic Non-Hodgkin‘s Lymphoma
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.